| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.073 | 0.02 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.076 | 0.02 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.02 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.09 | 0.02 |